Prostate Cancer Detection using TPI™

Spectrasonics' Tissue Parameter Imaging (TPI™) is a technology which can greatly enhance the utility of medical ultrasonic images. By analyzing the spectral content of received ultrasonic signals, TPI extracts tissue specific information which is not available using standard imaging systems. Clinical data from several thousand prostate biopsy procedures indicates that our patented TPI algorithms can differentiate between cancerous and benign tissue in the prostate. The ability to identify and target suspect tissue is particularly valuable in the prostate because the standard biopsy procedure is essentially random.

Spectrasonics has constructed a real-time TPI™ system for use in prostate imaging. At the Veterans' Administration Hospital in Northport, NY and at the Stony Brook University Hospital in Stony Brook, NY clinical trials are currently underway using this system to guide biopsy needles to sites in the prostate that are likely to be cancerous. An analysis performed by the Riverside Research Institute indicates that the use of TPI in this application could increase the cancer detection rate by up to 50%. More than one million prostate biopsies are performed each year and studies based on subsequent repeat biopsies show that these procedures fail to detect existing cancer up to 50% of the time. With approximately 20% of prostate biopsies yielding positive results, TPI could detect an additional 100,000 cancers each year, which are currently missed at the initial biopsy.

Eventually the TPI technique will be extended to detect cancer in other organs and also to detect the changes that occur as tissue is treated using the Spectrasonics' HIFU therapy system. This would provide a way of monitoring the HIFU therapy process in real-time. Ultimately, TPI technology should provide multiple benefits by both identifying pathological tissue and monitoring and controlling its treatment.

Intellectual Property

Spectrasonics has negotiated an exclusive worldwide licensing agreement with Cornell Research Foundation and Riverside Research Institute for the Tissue Parameter Imaging Technology described above. TPI is protected by several patents as well as copyrighted software relating to the use of spectral analysis to discriminate prostate disease. Furthermore, a proprietary lookup table at the heart of the TPI system constitutes an additional barrier to potential competition.

© 2004 Spectrasonics, Inc.

Top of page